HMOX1 and lung disorder: However, our prior studies in mice, may explain how oral 4 F that has low systemic absorption [9,11,12], by targeting gut inflammation, altered microbiome products, lipids and bioactive lipids, can have a major favorable impact on systemic oxidative stress, inflammation and lung disease and can upregulate in vivo pathways (such as HO-1) [16,32,33] that are key for host antiviral and anti-inflammatory responses against SARS-CoV-2 infection.